Assessment of breast cancer risk in Libyan women using the gail model

ElJilani, Mouna Mohamed; Shebani, Afaf A; Bishr, Amina M; Jalil, Hamza M Abdul; Dalyoum, Tarek M; Abudalla, Halema A; Abualroos, Reema Z; Alhodiri, Hamed O; Alemam, Hafsa A; Gusbi, Eman; Alhudiri, Inas M

doi:10.4103/ljms.ljms_26_20

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite recent efforts by Libyan health authorities to develop nationwide breast cancer screening programs [23], the unavailability of genetic diagnostics for people with familial breast and ovarian cancer remains a concern. Prediction of BRCA mutations in Libyan women has not been practiced, and this is the first study to use the BRCAPRO and BOADICEA scoring (≥ 10%) to predict BRCA1/2 gene mutations in women with BC who have a strong family history of BC, and to evaluate the efficacy of NCCN criteria.…”

Section: Discussionmentioning

confidence: 99%

A pivotal study on patients’ selection for BRCA1 and BRCA2 mutations by different models in Libyan breast cancer women

Elmaihub

Alhudiri²,

Elzagheid³

et al. 2023

Preprint

View full text Add to dashboard Cite

The BRCA mutation spectrum of familial breast cancer in Libya remains unknown. Several genetic models developed to predict the probability of BRCA1/2 mutations have not been applied in Libya, where the NCCN criteria are used for highly penetrating breast cancer susceptibility genes. We aimed to predict BRCA1/2 mutation probability in familial breast cancer and eligibility for genetic testing by using BOADICEA and BRCAPRO models and NCCN criteria. BRCA1/2 mutations were retrospectively predicted in 62 unrelated women with familial breast cancer between 2018 and 2021. Logistic regression, ROC analysis and AUC were used to compare NCCN referral criteria with the BRCAPRO and BOADICEA scores. Of 62 breast cancer patients, 32 (51.6%) (mean age 43.5±8 years) were predicted by both models as BRCA mutation carriers. BRCAPRO predicted BRCA1 and BRCA2 mutations in 27.4% and 41.9% of the women, respectively. BOADICEA predicted 8% for BRCA1 and 29% for BRCA2. At least one NCCN criterion was met by 50/62 women (80.6%). Only two criteria were statistically significant predictors in BRCAPRO and BOADICEA: breast cancer at ≤ 50 years with one or more close blood relatives with breast cancer, and breast cancer patient with a close relative of male breast cancer. For the two respective criteria, sensitivity was 0.78 and 0.89, specificity 0.33 and 0.39, AUC 0.72 and 0.75, PPV 78% and 27.5%, and NPV 67% and 97%. BODICEA and BRCAPRO models are suitable for recommending genetic testing for BRCA gene mutations. The NCCN criteria are too broad.

show abstract

Section: Discussionmentioning

confidence: 99%